Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 235

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma

Open access
Braun, David A., Ishii, Yuko, Walsh, Alice M., Van Allen, Eliezer M., Wu, Catherine J., Shukla, Sachet A., Choueiri, Toni K. · 2019 · JAMA Oncology

Abstract

Nivolumab, an immune checkpoint inhibitor (ICI) targeting the programmed death-1 (PD-1) pathway, is approved for metastatic clear cell renal cell carcinoma (ccRCC). 1 Loss-of-function (truncating) mutations in PBRM1, a PBAF-complex gene commonly mutated in ccRCC, were previously associated with clinical benefit from anti-PD-1 therapy in a smaller study, 2 Herein, this association was examined in an independent cohort from a randomized clinical trial 1 to determine whether PBRM1 alterations are a marker of response to ICI treatment.Methods | Archival tumor tissue (collected before antiangiogenic therapy) was obtained from patients enrolled in a randomized, phase 3 trial that demonstrated improved overall survival (OS) with nivolumab vs everolimus in patients with ccRCC who received prior antiangiogenic therapy. 1 This study was conducted under a secondary use protocol, approved by the Dana-Farber Cancer Institute.Written informed consent was obtained from participants.This post hoc analysis included 382 of 803 patients who were consented for genomic studies and passed quality control. 2 This cohort was not significantly different from the other 421 patients in response or progressionfree survival (PFS).Putative truncating mutations (frameshift insertion/deletion, nonsense, splice-site) 2 in PBRM1 were manually reviewed using the Integrative Genomics Viewer.3

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2019.3158

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 235

Metadata

Authors
Braun, D. A., Ishii, Y., Walsh, A. M., Van Allen, E. M., Wu, C. J., Shukla, S. A., & Choueiri, T. K.
Venue
JAMA Oncology
Published
2019-11-01
Volume
5
Issue
11
Pages
1631
ISSN
2374-2437 (ISSN-L)
OpenAlex
W2972162958
Cited by
235
References
3
FWCI
23.88
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. https://app.cochat.ai/papers/10.1001/jamaoncol.2019.3158
The paper
Braun, D. A., Ishii, Y., Walsh, A. M., Van Allen, E. M., Wu, C. J., Shukla, S. A., & Choueiri, T. K. (2019). Clinical Validation of PBRM1 Alterations as a Marker of Immune Checkpoint Inhibitor Response in Renal Cell Carcinoma. JAMA Oncology. https://doi.org/10.1001/jamaoncol.2019.3158

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.